RENX vs. COG, INHC, FDBK, KOO, C4XD, IUG, AREC, SAR, TRX, and OBD
Should you be buying Renalytix stock or one of its competitors? The main competitors of Renalytix include Cambridge Cognition (COG), Induction Healthcare Group (INHC), Feedback (FDBK), Kooth (KOO), C4X Discovery (C4XD), Intelligent Ultrasound Group (IUG), Arecor Therapeutics (AREC), Sareum (SAR), Tissue Regenix Group (TRX), and Oxford BioDynamics (OBD). These companies are all part of the "medical" sector.
Renalytix (LON:RENX) and Cambridge Cognition (LON:COG) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their community ranking, analyst recommendations, institutional ownership, valuation, earnings, risk, media sentiment, dividends and profitability.
Renalytix has a net margin of 0.00% compared to Cambridge Cognition's net margin of -29.25%. Cambridge Cognition's return on equity of -630.55% beat Renalytix's return on equity.
Renalytix has a beta of 1.91, suggesting that its share price is 91% more volatile than the S&P 500. Comparatively, Cambridge Cognition has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500.
In the previous week, Cambridge Cognition had 2 more articles in the media than Renalytix. MarketBeat recorded 2 mentions for Cambridge Cognition and 0 mentions for Renalytix. Cambridge Cognition's average media sentiment score of 0.51 beat Renalytix's score of 0.00 indicating that Cambridge Cognition is being referred to more favorably in the news media.
Cambridge Cognition has higher revenue and earnings than Renalytix. Cambridge Cognition is trading at a lower price-to-earnings ratio than Renalytix, indicating that it is currently the more affordable of the two stocks.
Cambridge Cognition received 82 more outperform votes than Renalytix when rated by MarketBeat users. However, 74.19% of users gave Renalytix an outperform vote while only 44.30% of users gave Cambridge Cognition an outperform vote.
21.4% of Renalytix shares are owned by institutional investors. Comparatively, 36.4% of Cambridge Cognition shares are owned by institutional investors. 31.6% of Renalytix shares are owned by insiders. Comparatively, 28.2% of Cambridge Cognition shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
Cambridge Cognition beats Renalytix on 9 of the 15 factors compared between the two stocks.
Get Renalytix News Delivered to You Automatically
Sign up to receive the latest news and ratings for RENX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RENX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Renalytix Competitors List
Related Companies and Tools
